Angela Bonham
Family · Terre Haute, INNPI 1689273773
Payments from drug & device makers
Across 338 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$995
- Boehringer Ingelheim$812
- Harmony Biosciences LLC$804
- Jazz Pharmaceuticals Inc.$547
- Sanofi$424
- plus $2K from 20 others
What the payments were for
- Food & beverage$6,06294%
- Education$3806%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 115 | $1,193 |
| AstraZeneca(2 entities) | 34 | $995 |
| Boehringer Ingelheim | 35 | $812 |
| Harmony Biosciences LLC | 22 | $804 |
| Jazz Pharmaceuticals Inc. | 19 | $547 |
| Sanofi | 17 | $424 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $253 |
| Grifols USA, LLC | 12 | $228 |
| Johnson & Johnson | 15 | $172 |
| Actelion Pharmaceuticals US, Inc. | 9 | $157 |
| Electromed, Inc. | 12 | $124 |
| Regeneron Healthcare Solutions, Inc. | 5 | $122 |
| AbbVie | 1 | $105 |
| Axsome Therapeutics, Inc. | 5 | $95 |
| Amgen | 4 | $75 |
| Baxter Healthcare | 2 | $48 |
| Genentech USA, Inc. | 4 | $43 |
| Pulmonx Corporation | 2 | $41 |
| Verona Pharma, Inc. | 2 | $39 |
| Inspire Medical Systems, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Boston Scientific | 1 | $16 |
| Fisher & Paykel Healthcare Inc | 1 | $15 |
| Merck | 1 | $14 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,442 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 460 | $409,331 |
| Sodium Oxybate | 12 | $224,133 |
| OfevNintedanib Esylate | 17 | $220,939 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $140,133 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 151 | $113,443 |
| Breo ElliptaFluticasone/Vilanterol | 123 | $56,171 |
| SymbicortBudesonide/Formoterol Fumarate | 54 | $19,531 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $17,992 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 641 | $17,521 |
| Spiriva HandihalerTiotropium Bromide | 21 | $16,653 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $15,692 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $13,333 |
| Spiriva RespimatTiotropium Bromide | 14 | $13,043 |
| SunosiSolriamfetol Hcl | 14 | $11,929 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $10,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,193 | $481,194613 claims |
| Boehringer IngelheimOfev, Combivent Respimat, Stiolto Respimat, Spiriva Respimat | $812 | $265,30781 claims |
| Grifols USA, LLCProlastin C | $228 | $140,13313 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $995 | $132,974205 claims |
| Axsome Therapeutics, Inc.Sunosi | $95 | $11,92914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Terre Haute
- Stephanie ArnoldTerre Haute$52K
- Daxton DuncanTerre Haute$31K
- Melinda FuquaTerre Haute$19K
- Tamara GormanTerre Haute$16K
- Kathy BannonTerre Haute$15K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.